These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20618838)

  • 1. Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy.
    Cozzoli A; Rolland JF; Capogrosso RF; Sblendorio VT; Longo V; Simonetti S; Nico B; De Luca A
    Neuropathol Appl Neurobiol; 2011 Apr; 37(3):243-56. PubMed ID: 20618838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, α-methyl prednisolone.
    Capogrosso RF; Cozzoli A; Mantuano P; Camerino GM; Massari AM; Sblendorio VT; De Bellis M; Tamma R; Giustino A; Nico B; Montagnani M; De Luca A
    Pharmacol Res; 2016 Apr; 106():101-113. PubMed ID: 26930420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1.
    De Luca A; Pierno S; Liantonio A; Cetrone M; Camerino C; Fraysse B; Mirabella M; Servidei S; Rüegg UT; Conte Camerino D
    J Pharmacol Exp Ther; 2003 Jan; 304(1):453-63. PubMed ID: 12490622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy.
    Cozzoli A; Capogrosso RF; Sblendorio VT; Dinardo MM; Jagerschmidt C; Namour F; Camerino GM; De Luca A
    Pharmacol Res; 2013 Jun; 72():9-24. PubMed ID: 23523664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice.
    Cozzoli A; Nico B; Sblendorio VT; Capogrosso RF; Dinardo MM; Longo V; Gagliardi S; Montagnani M; De Luca A
    Pharmacol Res; 2011 Nov; 64(5):482-92. PubMed ID: 21689754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
    Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
    J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A long-term treatment with taurine prevents cardiac dysfunction in mdx mice.
    Mele A; Mantuano P; De Bellis M; Rana F; Sanarica F; Conte E; Morgese MG; Bove M; Rolland JF; Capogrosso RF; Pierno S; Camerino GM; Trabace L; De Luca A
    Transl Res; 2019 Feb; 204():82-99. PubMed ID: 30347179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.
    Terrill JR; Pinniger GJ; Graves JA; Grounds MD; Arthur PG
    J Physiol; 2016 Jun; 594(11):3095-110. PubMed ID: 26659826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of prednisolone on the dystrophin-associated proteins in the blood-brain barrier and skeletal muscle of dystrophic mdx mice.
    Tamma R; Annese T; Capogrosso RF; Cozzoli A; Benagiano V; Sblendorio V; Ruggieri S; Crivellato E; Specchia G; Ribatti D; De Luca A; Nico B
    Lab Invest; 2013 May; 93(5):592-610. PubMed ID: 23528847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
    Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
    Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proof-of-concept validation of the mechanism of action of Src tyrosine kinase inhibitors in dystrophic mdx mouse muscle: in vivo and in vitro studies.
    Sanarica F; Mantuano P; Conte E; Cozzoli A; Capogrosso RF; Giustino A; Cutrignelli A; Cappellari O; Rolland JF; De Bellis M; Denora N; Camerino GM; De Luca A
    Pharmacol Res; 2019 Jul; 145():104260. PubMed ID: 31059789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests.
    Burdi R; Rolland JF; Fraysse B; Litvinova K; Cozzoli A; Giannuzzi V; Liantonio A; Camerino GM; Sblendorio V; Capogrosso RF; Palmieri B; Andreetta F; Confalonieri P; De Benedictis L; Montagnani M; De Luca A
    J Appl Physiol (1985); 2009 Apr; 106(4):1311-24. PubMed ID: 19131478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taurine deficiency, synthesis and transport in the mdx mouse model for Duchenne Muscular Dystrophy.
    Terrill JR; Grounds MD; Arthur PG
    Int J Biochem Cell Biol; 2015 Sep; 66():141-8. PubMed ID: 26239309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice.
    Spaulding HR; Quindry T; Hammer K; Quindry JC; Selsby JT
    J Appl Physiol (1985); 2019 Oct; 127(4):1058-1066. PubMed ID: 31295065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression patterns of regulatory RNAs, including lncRNAs and tRNAs, during postnatal growth of normal and dystrophic (mdx) mouse muscles, and their response to taurine treatment.
    Butchart LC; Terrill JR; Rossetti G; White R; Filipovska A; Grounds MD
    Int J Biochem Cell Biol; 2018 Jun; 99():52-63. PubMed ID: 29578051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial content is preserved throughout disease progression in the mdx mouse model of Duchenne muscular dystrophy, regardless of taurine supplementation.
    Barker RG; Wyckelsma VL; Xu H; Murphy RM
    Am J Physiol Cell Physiol; 2018 Apr; 314(4):C483-C491. PubMed ID: 29351413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice.
    Sali A; Many GM; Gordish-Dressman H; van der Meulen JH; Phadke A; Spurney CF; Cnaan A; Hoffman EP; Nagaraju K
    PLoS One; 2013; 8(7):e66617. PubMed ID: 23843959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological control of cellular calcium handling in dystrophic skeletal muscle.
    Ruegg UT; Nicolas-Métral V; Challet C; Bernard-Hélary K; Dorchies OM; Wagner S; Buetler TM
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S155-61. PubMed ID: 12206810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of fish oil containing eicosapentaenoic acid and docosahexaenoic acid on dystrophic mdx mice.
    Fogagnolo Mauricio A; Minatel E; Santo Neto H; Marques MJ
    Clin Nutr; 2013 Aug; 32(4):636-42. PubMed ID: 23218947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research.
    Muntoni F; Fisher I; Morgan JE; Abraham D
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S162-5. PubMed ID: 12206811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.